PPARα activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 291, Issue 6, 2006, Pages

  Subramanian, Savitha ^a   DeRosa, Michael A ^a   Bernal Mizrachi, Carlos ^a   Laffely, Nicholas ^a   Cade, William T ^a   Yarasheski, Kevin E ^a   Cryer, Philip E ^a   Semenkovich, Clay F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dexamethasone; Insulin sensitivity; Metabolic syndrome; Peroxisome proliferator activated receptor

Indexed keywords

CHOLESTEROL; DEXAMETHASONE; FENOFIBRATE; GLUCOCORTICOID; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ANTILIPEMIC AGENT;

ADULT; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLUCONEOGENESIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLIC PARAMETERS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; BLOOD PRESSURE MONITORING; FOREARM; GLUCOSE CLAMP TECHNIQUE; METABOLISM; PHYSIOLOGY; VASCULARIZATION;

ADULT; ANTILIPEMIC AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DEXAMETHASONE; FEMALE; FOREARM; GLUCOCORTICOIDS; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN RESISTANCE; MALE; PPAR ALPHA; PROCETOFEN; REGIONAL BLOOD FLOW;

EID: 33845462872     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00230.2006     Document Type: Article

References (36)

1. Alexander CM, Landsman PB, Teutsch SM, and Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52: 1210-1214, 2003.
2. Andrew R, Gale CR, Walker BR, Seckl JR, and Martyn CN. Glucocorticoid metabolism and the metabolic syndrome: associations in an elderly cohort. Exp Clin Endocrinol Diabetes 110: 284-290, 2002.
3. Ansquer JC, Foucher C, Rattier S, Taskinen MR, and Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45: 485-493, 2005.
4. Avogaro A, Miola M, Favaro A, Gottardo L, Pacini G, Manzato E, Zambon S, Sacerdoti D, de Kreutzenberg S, Piliego T, Tiengo A, and Del Prato S. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest 31: 603-609, 2001.
5. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC, Coleman T, Mecham RP, Kelly DP, and Semenkovich CF. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 9: 1069-1075, 2003.
6. Brotman DJ, Girod JP, Garcia MJ, Patel JV, Gupta M, Posch A, Saunders S, Lip GY, Worley S, and Reddy S. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab 90: 3202-3208, 2005.
7. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, and Reitman ML. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 277: 24484-24489, 2002.
8. Du X, Edelstein D, Obici S, Higham N, Zou MH, and Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing fatty acid oxidation. J Clin Invest 116: 1071-1080.
9. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, and Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642, 2000.
10. Jeng CY, Sheu WH, Fuh MM, Shieh SM, Chen YD, and Reaven GM. Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. J Clin Endocrinol Metab 81: 2550-2553, 1996.
11. Kahn R, Buse J, Ferrannini E, and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: 2289-2304, 2005.
12. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, and Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861, 2005.
13. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, and LeRoith D. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52: 1770-1778, 2003.
14. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, and Mullins JJ. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94: 14924-14929, 1997.
15. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, and Zhou G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem 276: 31521-31527, 2001.
16. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA. Peroxisome proliferator-activated receptors α and β are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410.
17. Lewington S, Clarke R, Qizilbash N, Peto R, and Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-1913, 2002.
18. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, and Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347: 797-805, 2002.
19. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, and Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170, 2001.
20. Mussoni L, Mannucci L, Sirtori C, Pazzucconi F, Bonfardeci G, Cimminiello C, Notarbartolo A, Scafidi V, Bittolo Bon G, Alessandrini P, Nenci G, Parise P, Colombo L, Piliego T, and Tremoli E. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis 148: 397-406, 2000.
21. Oliver MF, Heady JA, Morris JN, and Cooper JWHO. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 316: 379-385, 1980.
22. Oliver MF, Heady JA, Morris JN, and Cooper JWHO. Cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 324: 600-604, 1984.
23. Reeds DN, Yarasheski KE, Fontana L, Cade WT, Laciny E, DeMoss A, Patterson BW, Powderly WG, and Klein S. Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab 290: E47-E53, 2006.
24. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-418, 1999.
25. Shen DC, Fuh MM, Shieh SM, Chen YD, and Reaven GM. Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 73: 503-510, 1991.
26. Staels B and Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470, 2005.
27. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, and Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 87: 4872-4878, 2002.
28. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, and Behar S. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 166: 737-741, 2006.
29. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102: 21-27, 2000.
30. Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, and Semenkovich CF. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 107: 1025-1034, 2001.
31. Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, Stewart PM, and Kumar S. 11Beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 89: 4755-4761, 2004.
32. Vega GL, Cater NB, Hadizadeh DR, 3rd Meguro S, and Grundy SM. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin Pharmacol Ther 74: 236-244, 2003.
33. Whitelaw DC, Smith JM, and Nattrass M. Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. Diabetes Obes Metab 4: 187-194, 2002.
34. Whitworth JA, Mangos GJ, and Kelly JJ. Cushing, cortisol, and cardiovascular disease. Hypertension 36: 912-916, 2000.
35. Wilkinson IB and Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 52: 631-646, 2001.
36. Yong QW, Thavintharan S, Cheng A, and Chew LS. The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome. Ann Acad Med Singapore 28: 778-782, 1999.